Do analysts prefer KIDS or INGN?

OrthoPediatrics currently has a consensus target price of $26.50, suggesting a potential upside of 22.40%. Given OrthoPediatrics' stronger consensus rating and higher probable upside, equities research analysts clearly believe OrthoPediatrics is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OrthoPediatrics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better valuation and earnings, KIDS or INGN?

Inogen has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OrthoPediatrics $252.72M 2.24 -$39.65M -$1.68 N/A Inogen $348.67M 0.47 -$22.75M -$0.90 N/A

Is KIDS or INGN more profitable?

Inogen has a net margin of -6.94% compared to OrthoPediatrics' net margin of -15.72%. OrthoPediatrics' return on equity of -8.10% beat Inogen's return on equity. Company Net Margins Return on Equity Return on Assets OrthoPediatrics -15.72% -8.10% -5.54% Inogen -6.94% -13.17% -8.36%

Does the media refer more to KIDS or INGN?

In the previous week, OrthoPediatrics had 1 more articles in the media than Inogen. MarketBeat recorded 4 mentions for OrthoPediatrics and 3 mentions for Inogen. OrthoPediatrics' average media sentiment score of 0.61 beat Inogen's score of 0.61 indicating that OrthoPediatrics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OrthoPediatrics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inogen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer INGN or SSII?

SS Innovations International has a consensus target price of $7.00, suggesting a potential upside of 165.15%. Given SS Innovations International's higher probable upside, analysts clearly believe SS Innovations International is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 SS Innovations International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer INGN or SSII?

In the previous week, SS Innovations International had 5 more articles in the media than Inogen. MarketBeat recorded 8 mentions for SS Innovations International and 3 mentions for Inogen. Inogen's average media sentiment score of 0.61 beat SS Innovations International's score of 0.49 indicating that Inogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inogen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SS Innovations International 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend DCTH or INGN?

Delcath Systems presently has a consensus price target of $23.17, indicating a potential upside of 50.82%. Given Delcath Systems' stronger consensus rating and higher possible upside, research analysts plainly believe Delcath Systems is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Delcath Systems 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable earnings and valuation, DCTH or INGN?

Delcath Systems has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Delcath Systems $85.23M 6.25 $2.70M $0.01 1,536.00 Inogen $348.67M 0.47 -$22.75M -$0.90 N/A

Is DCTH or INGN more profitable?

Delcath Systems has a net margin of 0.56% compared to Inogen's net margin of -6.94%. Delcath Systems' return on equity of 0.46% beat Inogen's return on equity. Company Net Margins Return on Equity Return on Assets Delcath Systems 0.56% 0.46% 0.42% Inogen -6.94% -13.17% -8.36%

Does the media refer more to DCTH or INGN?

In the previous week, Delcath Systems had 1 more articles in the media than Inogen. MarketBeat recorded 4 mentions for Delcath Systems and 3 mentions for Inogen. Inogen's average media sentiment score of 0.61 beat Delcath Systems' score of -0.33 indicating that Inogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Delcath Systems 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Inogen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate BWAY or INGN?

Brainsway currently has a consensus target price of $18.20, indicating a potential upside of 54.63%. Given Brainsway's stronger consensus rating and higher possible upside, research analysts plainly believe Brainsway is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainsway 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable valuation & earnings, BWAY or INGN?

Brainsway has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainsway $52.22M 9.07 $7.57M $0.44 26.75 Inogen $348.67M 0.47 -$22.75M -$0.90 N/A

Is BWAY or INGN more profitable?

Brainsway has a net margin of 15.65% compared to Inogen's net margin of -6.94%. Brainsway's return on equity of 12.74% beat Inogen's return on equity. Company Net Margins Return on Equity Return on Assets Brainsway 15.65% 12.74% 8.17% Inogen -6.94% -13.17% -8.36%

Does the media refer more to BWAY or INGN?

In the previous week, Inogen had 1 more articles in the media than Brainsway. MarketBeat recorded 3 mentions for Inogen and 2 mentions for Brainsway. Brainsway's average media sentiment score of 1.18 beat Inogen's score of 0.61 indicating that Brainsway is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Brainsway 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inogen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend INGN or TCMD?

Tactile Systems Technology has a consensus target price of $38.40, suggesting a potential upside of 71.12%. Given Tactile Systems Technology's stronger consensus rating and higher possible upside, analysts plainly believe Tactile Systems Technology is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Tactile Systems Technology 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67

Does the media refer more to INGN or TCMD?

In the previous week, Tactile Systems Technology had 1 more articles in the media than Inogen. MarketBeat recorded 4 mentions for Tactile Systems Technology and 3 mentions for Inogen. Tactile Systems Technology's average media sentiment score of 0.63 beat Inogen's score of 0.61 indicating that Tactile Systems Technology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inogen 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tactile Systems Technology 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Inogen (INGN) Competitors

$6.18 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$6.18 0.00 (0.00%)

As of 10/9/2026 07:30 PM Eastern

Compare

INGN vs. KIDS, SSII, DCTH, BWAY, and TCMD

Should you buy Inogen stock or one of its competitors? Inogen's main competitors and comparable companies include OrthoPediatrics (KIDS), SS Innovations International (SSII), Delcath Systems (DCTH), Brainsway (BWAY), and Tactile Systems Technology (TCMD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Inogen compare to OrthoPediatrics?

OrthoPediatrics (NASDAQ:KIDS) and Inogen (NASDAQ:INGN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership, media sentiment and dividends.

OrthoPediatrics has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market. Comparatively, Inogen has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

In the previous week, OrthoPediatrics had 1 more articles in the media than Inogen. MarketBeat recorded 4 mentions for OrthoPediatrics and 3 mentions for Inogen. OrthoPediatrics' average media sentiment score of 0.61 beat Inogen's score of 0.61 indicating that OrthoPediatrics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OrthoPediatrics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inogen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Inogen has higher revenue and earnings than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OrthoPediatrics	$252.72M	2.24	-$39.65M	-$1.68	N/A
Inogen	$348.67M	0.47	-$22.75M	-$0.90	N/A

Inogen has a net margin of -6.94% compared to OrthoPediatrics' net margin of -15.72%. OrthoPediatrics' return on equity of -8.10% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OrthoPediatrics	-15.72%	-8.10%	-5.54%
Inogen	-6.94%	-13.17%	-8.36%

OrthoPediatrics currently has a consensus target price of $26.50, suggesting a potential upside of 22.40%. Given OrthoPediatrics' stronger consensus rating and higher probable upside, equities research analysts clearly believe OrthoPediatrics is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

69.1% of OrthoPediatrics shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 32.5% of OrthoPediatrics shares are owned by insiders. Comparatively, 2.5% of Inogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

OrthoPediatrics beats Inogen on 9 of the 17 factors compared between the two stocks.

How does Inogen compare to SS Innovations International?

Inogen (NASDAQ:INGN) and SS Innovations International (NASDAQ:SSII) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, institutional ownership, media sentiment and risk.

Inogen has a net margin of -6.94% compared to SS Innovations International's net margin of -23.73%. Inogen's return on equity of -13.17% beat SS Innovations International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-6.94%	-13.17%	-8.36%
SS Innovations International	-23.73%	-26.77%	-15.01%

Inogen has a beta of 1.5, meaning that its share price is 50% more volatile than the broader market. Comparatively, SS Innovations International has a beta of -1.79, meaning that its share price is 279% less volatile than the broader market.

SS Innovations International has a consensus target price of $7.00, suggesting a potential upside of 165.15%. Given SS Innovations International's higher probable upside, analysts clearly believe SS Innovations International is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

89.9% of Inogen shares are owned by institutional investors. 2.5% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

SS Innovations International has lower revenue, but higher earnings than Inogen. SS Innovations International is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$348.67M	0.47	-$22.75M	-$0.90	N/A
SS Innovations International	$42.49M	12.45	-$12.13M	-$0.06	N/A

In the previous week, SS Innovations International had 5 more articles in the media than Inogen. MarketBeat recorded 8 mentions for SS Innovations International and 3 mentions for Inogen. Inogen's average media sentiment score of 0.61 beat SS Innovations International's score of 0.49 indicating that Inogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inogen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SS Innovations International	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Inogen beats SS Innovations International on 11 of the 16 factors compared between the two stocks.

How does Inogen compare to Delcath Systems?

Delcath Systems (NASDAQ:DCTH) and Inogen (NASDAQ:INGN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, Delcath Systems had 1 more articles in the media than Inogen. MarketBeat recorded 4 mentions for Delcath Systems and 3 mentions for Inogen. Inogen's average media sentiment score of 0.61 beat Delcath Systems' score of -0.33 indicating that Inogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Delcath Systems	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inogen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 19.4% of Delcath Systems shares are held by company insiders. Comparatively, 2.5% of Inogen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Delcath Systems has a net margin of 0.56% compared to Inogen's net margin of -6.94%. Delcath Systems' return on equity of 0.46% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.56%	0.46%	0.42%
Inogen	-6.94%	-13.17%	-8.36%

Delcath Systems has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Inogen has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

Delcath Systems has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	6.25	$2.70M	$0.01	1,536.00
Inogen	$348.67M	0.47	-$22.75M	-$0.90	N/A

Delcath Systems presently has a consensus price target of $23.17, indicating a potential upside of 50.82%. Given Delcath Systems' stronger consensus rating and higher possible upside, research analysts plainly believe Delcath Systems is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Delcath Systems beats Inogen on 12 of the 17 factors compared between the two stocks.

How does Inogen compare to Brainsway?

Brainsway (NASDAQ:BWAY) and Inogen (NASDAQ:INGN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

Brainsway currently has a consensus target price of $18.20, indicating a potential upside of 54.63%. Given Brainsway's stronger consensus rating and higher possible upside, research analysts plainly believe Brainsway is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Brainsway has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainsway	$52.22M	9.07	$7.57M	$0.44	26.75
Inogen	$348.67M	0.47	-$22.75M	-$0.90	N/A

Brainsway has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market. Comparatively, Inogen has a beta of 1.5, suggesting that its share price is 50% more volatile than the broader market.

In the previous week, Inogen had 1 more articles in the media than Brainsway. MarketBeat recorded 3 mentions for Inogen and 2 mentions for Brainsway. Brainsway's average media sentiment score of 1.18 beat Inogen's score of 0.61 indicating that Brainsway is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Brainsway	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inogen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

30.1% of Brainsway shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 19.0% of Brainsway shares are owned by insiders. Comparatively, 2.5% of Inogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Brainsway has a net margin of 15.65% compared to Inogen's net margin of -6.94%. Brainsway's return on equity of 12.74% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainsway	15.65%	12.74%	8.17%
Inogen	-6.94%	-13.17%	-8.36%

Summary

Brainsway beats Inogen on 12 of the 17 factors compared between the two stocks.

How does Inogen compare to Tactile Systems Technology?

Inogen (NASDAQ:INGN) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Tactile Systems Technology has a consensus target price of $38.40, suggesting a potential upside of 71.12%. Given Tactile Systems Technology's stronger consensus rating and higher possible upside, analysts plainly believe Tactile Systems Technology is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Tactile Systems Technology has higher revenue and earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$348.67M	0.47	-$22.75M	-$0.90	N/A
Tactile Systems Technology	$350.31M	1.45	$19.09M	$1.08	20.78

Inogen has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, Tactile Systems Technology has a beta of 0.82, indicating that its share price is 18% less volatile than the broader market.

In the previous week, Tactile Systems Technology had 1 more articles in the media than Inogen. MarketBeat recorded 4 mentions for Tactile Systems Technology and 3 mentions for Inogen. Tactile Systems Technology's average media sentiment score of 0.63 beat Inogen's score of 0.61 indicating that Tactile Systems Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inogen	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tactile Systems Technology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

89.9% of Inogen shares are owned by institutional investors. Comparatively, 83.4% of Tactile Systems Technology shares are owned by institutional investors. 2.5% of Inogen shares are owned by company insiders. Comparatively, 2.1% of Tactile Systems Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Tactile Systems Technology has a net margin of 7.10% compared to Inogen's net margin of -6.94%. Tactile Systems Technology's return on equity of 11.49% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-6.94%	-13.17%	-8.36%
Tactile Systems Technology	7.10%	11.49%	9.17%

Summary

Tactile Systems Technology beats Inogen on 13 of the 17 factors compared between the two stocks.

Get Inogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INGN vs. The Competition

Export

Metric	Inogen	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$164.02M	$5.49B	$7.25B	$13.28B
Dividend Yield	N/A	1.77%	2.52%	22.58%
P/E Ratio	-6.87	25.57	275.59	26.13
Price / Sales	0.47	71.28	595.29	89.84
Price / Cash	N/A	32.56	27.30	36.12
Price / Book	0.87	5.95	10.58	6.16
Net Income	-$22.75M	$146.14M	$3.50B	$381.12M
7 Day Performance	4.04%	-0.58%	-1.21%	-1.43%
1 Month Performance	16.38%	-2.13%	-4.02%	-3.36%
1 Year Performance	-24.26%	5.41%	7.17%	1.49%

Inogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INGN Inogen	1.0616 of 5 stars	$6.18 flat	N/A	-24.3%	$164.02M	$348.67M	N/A	753
KIDS OrthoPediatrics	2.935 of 5 stars	$22.89 +3.3%	$26.44 +15.5%	+32.8%	$578.60M	$252.72M	N/A	602
SSII SS Innovations International	1.5056 of 5 stars	$2.77 +3.7%	$7.00 +152.7%	-62.0%	$535.03M	$42.49M	N/A	483
DCTH Delcath Systems	3.019 of 5 stars	$15.87 +4.9%	$23.17 +46.0%	+46.8%	$524.99M	$85.23M	1,588.59	156
BWAY Brainsway	4.6286 of 5 stars	$12.23 -2.2%	$18.20 +48.8%	+56.1%	$502.36M	$60.70M	27.80	129	Positive News Gap Down High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INGN) was last updated on 10/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inogen (INGN) Competitors

INGN vs. KIDS, SSII, DCTH, BWAY, and TCMD

How does Inogen compare to OrthoPediatrics?

Summary

How does Inogen compare to SS Innovations International?

Summary

How does Inogen compare to Delcath Systems?

Summary

How does Inogen compare to Brainsway?

Summary

How does Inogen compare to Tactile Systems Technology?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INGN vs. The Competition

Inogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inogen (INGN) Competitors

INGN vs. KIDS, SSII, DCTH, BWAY, and TCMD

How does Inogen compare to OrthoPediatrics?

Which has more risk and volatility, KIDS or INGN?

Does the media refer more to KIDS or INGN?

Which has better valuation and earnings, KIDS or INGN?

Is KIDS or INGN more profitable?

Do analysts prefer KIDS or INGN?

Do institutionals and insiders hold more shares of KIDS or INGN?

Summary

How does Inogen compare to SS Innovations International?

Is INGN or SSII more profitable?

Which has more volatility & risk, INGN or SSII?

Do analysts prefer INGN or SSII?

Do insiders & institutionals hold more shares of INGN or SSII?

Which has stronger earnings and valuation, INGN or SSII?

Does the media prefer INGN or SSII?

Summary

How does Inogen compare to Delcath Systems?

Does the media refer more to DCTH or INGN?

Do institutionals and insiders believe in DCTH or INGN?

Is DCTH or INGN more profitable?

Which has more risk & volatility, DCTH or INGN?

Which has preferable earnings and valuation, DCTH or INGN?

Do analysts recommend DCTH or INGN?

Summary

How does Inogen compare to Brainsway?

Do analysts rate BWAY or INGN?

Which has preferable valuation & earnings, BWAY or INGN?

Which has more volatility and risk, BWAY or INGN?

Does the media refer more to BWAY or INGN?

Do insiders and institutionals believe in BWAY or INGN?

Is BWAY or INGN more profitable?

Summary

How does Inogen compare to Tactile Systems Technology?

Do analysts recommend INGN or TCMD?

Which has better earnings and valuation, INGN or TCMD?

Which has more risk and volatility, INGN or TCMD?

Does the media refer more to INGN or TCMD?

Do institutionals & insiders hold more shares of INGN or TCMD?

Is INGN or TCMD more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INGN vs. The Competition

Inogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools